title: Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling.
abstract: Thymidine kinase 1 (TK1) is a key enzyme involved in the synthesis of DNA precursors and thus, cell proliferation-dependent. Antibodies against TK1 have provided attractive tools for cancer diagnosis. Expression of TK1 in 158 non-small cell lung cancer (NSCLC) patients with 59 adenocarcinoma (AC) and 99 squamous cell carcinoma (SCC) was determined by anti-TK1 monoclonal antibody (mAb) 1E3 (AC, n=50; SCC, n=70). Parallel tumor sections were stained for Ki-67 (MIB-1), and TK1 expression was also investigated with anti-TK1 chicken IgY Ab (AC, n=9; SCC, n=29; normal lung tissues, n=10). In one AC and one SCC patient, gene profiling was done by cDNA array. Using the mAb 1E3, a significantly higher TK1 labeling index (LI) of AC patients was found (68%) compared to the LI of Ki-67 (36%). This difference was due to a significantly higher TK1 LI of tumor stage II and grade 2. Although no difference in the LI of TK1 and Ki-67 of SCC patients was found (54 vs. 53%), significantly higher TK1 LI of SCC patients of tumor grade 1 was found. Using the anti-TK1 IgY Ab, a higher TK1 LI of AC patients (78%) and SCC patients (66%) was found compared to staining with mAb 1E3 (68 vs. 54%), but it was not significantly different. Samples stained only for TK1 represented mostly tumor stages I and II and grades 1 and 2 of both AC and SCC. AC patients whose samples stained only for Ki-67 were found to be in stage I and grade 1. cDNA profiling showed that the expression of BRCA1, cyclin B1 and cdc2p34 was higher in AC compared to SCC, while the expression of IGFBP-3 and EGFR was higher in SCC. TK1 is apparently a more reliable marker in AC patients than Ki-67. However, a combination of the two markers may help identify patients of different stages and grades more efficiently, and cyclin/kinase complexes and growth factors/receptors may be useful markers in distinguishing AC from SCC.
authors.affiliation: Hubei Cancer Hospital, Wuhan, China.
authors.forename: Yongrong
authors.initials: Y
authors.lastname: Mao
authors.forename: Jainping
authors.initials: J
authors.lastname: Wu
authors.forename: Sven
authors.initials: S
authors.lastname: Skog
authors.forename: Staffan
authors.initials: S
authors.lastname: Eriksson
authors.forename: Yiwei
authors.initials: Y
authors.lastname: Zhao
authors.forename: Ji
authors.initials: J
authors.lastname: Zhou
authors.forename: Qimin
authors.initials: Q
authors.lastname: He
mesh_terms: D000236:Adenoma / Q000235:genetics / Q000473:pathology; D000595:Amino Acid Sequence; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D002455:Cell Division / Q000235:genetics*; D016172:DNA Fingerprinting; D018076:DNA, Complementary / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008969:Molecular Sequence Data; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000737:chemistry; D013937:Thymidine Kinase / Q000235:genetics
chemical_list: D018076:DNA, Complementary; D019394:Ki-67 Antigen; D010446:Peptide Fragments; D013937:Thymidine Kinase; C092717:thymidine kinase 1